.jpg)
- About Us
- Our Aims & Objectives
- Organisation
- About The EPDA
- Patrons
- Board Members
- Administration Board Responsibilities
- Administrative Team
- Member Organisations
- Medical Advisory Board
- European Young PWP
- Associated Members
- Associated Organisations
- General Assembly
- Memorandum & Articles of Association
- Registration Document
- Business Plan
- Our Standpoints on Important Issues
- Annual Reports
- Bank Account Details
- Partners & Sponsors
- Membership
- Activities & Events
- Projects
- News & Publications
- PD Information
- Further Resources
Medication Info
- Levodopa
- COMT-Inhibitors
- Dopamine Agonists
- MAO-B Inhibitors
- Neurosurgery
- Diagnostic Products
- Other products
-
Dopamine Agonists
- Apomorphine (APO-go®)
- Cabergolide
- Pergolide
- Pramipexol
- Ropinirole (REQUIP®)
- Rotigotine (Neupro®)
.gif){kind=small}
Apomorphine information courtesy of Britannia Pharmaceuticals Limited
Last updated 25 July 2007
This section provides a summary of the drug information for APO-go® (apomorphine hydrochloride). It is still important that you read the full package leaflet that accompanies the product carefully before you start to take any medication. If you have any further questions
about your Pd medication,
or other aspects of your Pd treatment, you should discuss these with your doctor or other healthcare professional.
Apomorphine
APO-go® Pen (UK)
APO-go® 20mg-2ml ampoules (UK)
APO-go® PFS (UK)
Click on photos to enlarge
  Australia & New Zealand |
Apomine® | Mayne Pharma |
|---|---|---|
   Austria, Germany & Switzerland |
APO-go® | Cephalon |
 Greece |
APO-go® | ITF Hellas |
 Holland |
APO-go® | Apotheekzorg |
 Israel |
APO-go® | Teva |
 North America |
Apokyn® | Vernalis |
  Portugal & Spain |
APO-go® | Italfarmaco |
      Scandinavia |
APO-go® | Nordic Infucare |
 Republic of Ireland |
APO-go® | Clonmel Healthcare Ltd |
 Turkey |
APO-go® | Gen Ilac |
 UK |
APO-go® | Britannia Pharmaceuticals Ltd |
Availability - Formulation
There are currently a maximum of three APO-go® presentations available. Approved presentations may vary between countries:
- APO-go® PEN 10mg/ml
(pens for injection) - APO-go® Ampoules 10mg/ml available in 2ml and 5ml ampoules
(solution for injection) - APO-go® PFS 5mg/ml Solution for Infusion in Pre-filled Syringe
( Pre-filled Syringes)
Downloads
Please click on the links below to download
detailed information on the specific APO-go® medication, its handling and use.
Further detailed information on APO-go® products can be downloaded via the EPDA wesite (www.epda.eu.com/medinfo/apomorphine).
Patient Information Leaflets available for download
(Adobe Acrobat pdf files)
- APO-go® PEN 10 mg/ml Solution for Injection
- APO-go® AMPOULES 10 mg/ml Solution for Injection
- APO-go® PFS 5mg/ml Solution for Infusion in Pre-filled Syringe
UK Summary of Product Characteristics available for download
(Adobe Acrobat pdf files)
- APO-go® PEN 10 mg/ml Solution for Injection
- APO-go® AMPOULES 10 mg/ml Solution for Injection
- APO-go® PFS 5mg/ml Solution for Infusion in Pre-filled Syringe
Useful Links & References
- APO-go® Website: www.apomorphine.co.uk
- Britannia Website: www.britannia-pharm.co.uk
Further Information
Britannia Pharmaceuticals Limited
41-51 Brighton Road
Redhill
Surrey
RH1 6YS
United Kingdom
t: +44 (0)1737 773741
f: +44 (0)1737 762672
Copyright © EPDA. All rights reserved.
